Barely Significant
← all excerpts

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups.

Thrombosis · 2013 · PMC3885278 · PMID 24455237

2
hedged sentences
closest p
boldest claim

The sentences

showed a trendno p-value reported
Analysing the site of bleeding, rivaroxaban showed a trend towards increased risk of major upper gastrointestinal bleeding and major lower gastrointestinal bleeding, while dabigatran increased the risk of major lower gastrointestinal bleeding ( Figure 7 ).

also in 53,322 other papers

may be significantno p-value reported
Beyond statistical significance, subgroup analyses suggest that the net benefit of the NOAC seems better than that of warfarin in situations in which quality of oral anticoagulation is poor, given that thromboembolic complications, major bleeding, and mortality may be decreased, as well as in patients with prior stroke or transient ischemic attack, particularly if they have concomitant predictive factors for developing ICB (e.g., leukoaraiosis) [ 64 ], given that the absolute risk reduction in ICB may be significant.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.